Akeso, Inc. (HK:9926) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Akeso, Inc. has announced that China’s National Medical Products Administration (NMPA) approved the supplemental New Drug Application for cadonilimab as a first-line treatment for advanced gastric cancer, marking a significant advancement in immunotherapy options for the disease. The drug, which addresses the efficacy gap in patients with low or negative PD-L1 expression, demonstrated a significant improvement in overall survival during Phase III clinical trials. This approval may pave the way for broader applications in various cancer treatments, as the company is conducting multiple clinical trials for different indications.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.